Accelerating Life- Changing Medicines

We are knowledgeable, confident and results-oriented experts who work with a sense of urgency to identify, acquire and accelerate development and delivery of transformative medicines for patients.

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of trans...

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWI...

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a...

All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage cl...

1/3

Our Science

We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.

Learn More

Meet Our Leadership

We are led by a team of veteran biopharma executives who bring exceptional track records of developing and commercializing transformative therapies.

Learn More

Courageous Caring

Guided by our key cultural value of Courageous Caring, and driven by a sense of urgency, we are building an innovative biopharma company that aims to invest in, develop and commercialize clinically meaningful therapies.

Who We Are

We Care as Scientists, and We Care as People

We have the right blend of scientific, medical, operational and corporate experience to identify, develop and commercialize treatments with the potential to dramatically transform patients’ lives.

Our Story

Our Work

Accelerating Transformative Therapies

We are actively investigating the potential of izokibep and lonigutamab in diseases where differentiated inhibition of validated targets may help to address unmet patient needs.

Our Pipeline

Careers

Join a team that Courageously Cares

ACELYRIN is building a biopharma company with a corporate culture of Courageous Caring - placing patients first and embracing the concept that all of us together are better than any one of us alone. We strive to address the most basic human needs: to live a productive life free from disease.

Learn More

Latest Press Releases

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

Press Release

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Press Release

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

See All Press Releases